BridgeBio Pharma (BBIO) Current Leases (2019 - 2026)

BridgeBio Pharma has disclosed Current Leases across 8 years of filings, most recently posting $4.4 million for Q1 2026.

• Current Leases for Q1 2026 came in at $4.4 million, down 14.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.4 million (down 14.78% YoY), and the FY2025 annual result was $6.2 million, up 37.42% from the prior year.
• Current Leases came in at $4.4 million for Q1 2026 at BridgeBio Pharma, down from $6.2 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $6.2 million in Q4 2025 to a low of $3.7 million in Q1 2023.
• The 5-year median for Current Leases is $4.4 million (2026), against an average of $4.5 million.
• Across the five-year window, Current Leases retreated 25.58% in 2022 and surged 37.42% in 2025, its largest moves.
• BridgeBio Pharma's Current Leases stood at $3.7 million in 2022, then climbed by 12.33% to $4.1 million in 2023, then rose by 9.16% to $4.5 million in 2024, then jumped by 37.42% to $6.2 million in 2025, then decreased by 28.31% to $4.4 million in 2026.
• The last three Current Leases figures came in at $4.4 million (Q1 2026), $6.2 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.